About Biotheranostics
Biotheranostics: Revolutionizing Cancer Treatment with Molecular-Based Tests
Biotheranostics is a leading biotechnology company that specializes in developing and discovering proprietary molecular-based tests to provide physicians with actionable information to guide cancer treatment. The company's mission is to improve patient outcomes by providing personalized diagnostic solutions that enable physicians to make informed decisions about cancer treatment.
With over a decade of experience in the field, Biotheranostics has established itself as a pioneer in the development of innovative diagnostic tools for cancer patients. The company's flagship product, Breast Cancer Index (BCI), is a genomic test that helps predict the likelihood of breast cancer recurrence and guides treatment decisions for early-stage breast cancer patients.
The BCI test analyzes the expression levels of seven genes associated with estrogen receptor-positive (ER+) breast cancers, which account for approximately 70% of all breast cancers. By measuring these gene expression levels, BCI provides physicians with valuable information about the risk of recurrence and helps them determine whether extended endocrine therapy beyond five years would be beneficial for their patients.
In addition to BCI, Biotheranostics also offers another molecular-based test called CancerTYPE ID®. This test uses gene expression profiling technology to identify the primary site of metastatic tumors when it is uncertain or unknown. This information can help guide treatment decisions and improve patient outcomes by ensuring that they receive appropriate therapy based on their specific tumor type.
Biotheranostics' commitment to innovation and excellence has earned it numerous accolades over the years. In 2019, Frost & Sullivan recognized Biotheranostics as "Company of the Year" in recognition of its outstanding achievements in developing innovative diagnostic solutions for oncology patients.
The company's success can be attributed not only to its cutting-edge technology but also its team of world-class scientists and researchers who are dedicated to advancing personalized medicine through precision diagnostics. With an unwavering commitment to improving patient outcomes through innovation, Biotheranostics continues to lead the way in revolutionizing cancer treatment with molecular-based tests.
In conclusion, if you or someone you know has been diagnosed with breast or metastatic cancer, consider asking your physician about Biotheranostic's genomic testing options like Breast Cancer Index (BCI) or CancerTYPE ID® . These tests may provide valuable insights into your specific condition and help guide personalized treatment decisions tailored specifically towards your needs - ultimately improving your chances at beating this disease!